With snowballing healthcare spending and the emergence of new modalities of treatments, discussions are heating up around revisiting the scope of health coverage on pharmaceuticals, with the Ministry of Finance (MOF) and payers advocating the mantra of “large risks with…
HOME > INTERVIEW
INTERVIEW
-
Pharma Industry Watered Down Original Proposals for Pricing Overhaul, Corrections Necessary: Kenporen Director
September 12, 2019
-
As New Era Dawns, Eisai CEO Says Pharma Could Be True Winner of 4th Industrial Revolution
May 8, 2019
-
Nichi-Iko to Leverage Synergies of Integration with Elmed Eisai: Sales Head
April 22, 2019
-
I’ve Done Everything I Can in 11 Years, Says Outgoing PMDA Chief
March 28, 2019
-
With HIV Back in Hand, Gilead Heading into Second Phase in Japan Market: Pres. Hermans
March 26, 2019
-
JMA Exec Matsumoto: CEA Scheme Merely a Supplemental Tool to Drug Pricing System, Continued Discussions Necessary
March 7, 2019
-
Interview: Pfizer Japan Looks to Offer High Quality Biosimilars with Go-It-Alone Strategy
February 2, 2018
-
Taiyo Pharma Eyeing 10 Trillion Yen Japanese Market, Looking to Use In-House Technologies to Develop New Products: COO
January 10, 2018
-
Chordia President Confident in Success of “Synthetic Lethality” Drug; Negotiated Directly with Takeda to Establish Startup
December 7, 2017
-
Takeda Eager to Build Life Science Hub in Shonan, Offer Research Environment Akin to US East Coast: Exec Hirate
October 24, 2017
-
Me Pharma Sees Opportunities in Low-Cost Strategy, Could Carve Out New Biz Models: President
August 14, 2017
-
Centerpiece of FPMAJ’s Lobbying Push Will Be Price Maintenance Premium: Chairman
April 14, 2017
-
Scohia Wants to Make Its “Carve Out” a Success Model for Japan Makers: CEO
April 5, 2017
-
Chugai to Execute Area-Based Strategy Centering on General Reps: Marketing Chief
March 6, 2017
-
Daiichi Sankyo Espha Eyes 50 Billion Yen Sales in 2020 with AGs as Growth Engine
February 28, 2017
-
Takeda’s Japan Biz “Going in Good Direction” towards 1st Underlying Sales Rise in 5 Years: Iwasaki
February 24, 2017
-
CEO Weber Says Takeda’s Ongoing Transformation “Irreversible”: Full Interview
February 8, 2017
-
MHLW’s Sakoi Calls on Industry to Transcend Corporate Boundaries, Join Pricing Reform Debate
January 16, 2017
-
Interview: Metgluco, AGs, and Diagnostics 3 Biz Pillars for New Sumitomo Dainippon Subsidiary
December 2, 2016
-
Interview: Ex-Astellas Boss Takenaka Urges Mid-Size Makers to Be More Open to Academia in Pathological Research
August 18, 2016
ページ
As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In my home country of Australia, there is a famous candy called “Minties”. Minties has a long-running advertising campaign, presenting comical situations, with the caption, “It’s moments like these.” The phase has become part of the Aussie vernacular, meaning in…